Abstract
Serological presence of anti-double-stranded DNA (anti-dsDNA) antibodies is a common phenomenon in cancer patients. Some patients with relatively high levels of anti-dsDNA antibodies may have a better prognosis, indicating the potential antitumor roles of anti-dsDNA antibodies. To delineate the role and mechanisms of anti-dsDNA antibodies in delaying tumor development, here we prepared a panel of anti-dsDNA monoclonal antibodies (mAbs) and assessed their antitumor effects both in vitro and in vivo. After immunization of BALB/c mice with DNA from SP2/0 tumor cells, 12 anti-dsDNA mAbs were obtained. Among these mAbs, mAb 2G8 exhibited the strongest cytotoxicity to Wehi164 cells in vitro and significantly inhibited the growth of tumor in vivo. This mAb 2G8–mediated antitumor effect was mainly exerted by triggering apoptosis, as evidenced by Annexin V staining and DNA fragmentation. Further, the expression of antiapoptotic genes Bcl-2 and Bcl-xL was downregulated while that of pro-apoptotic gene Bax was upregulated, suggesting the involvement of mitochondrial apoptotic pathway. Taken together, dsDNA-specific mAb 2G8 revealed promising tumor-suppressive activity by inducing apoptosis, which provides a possible new strategy for the development of tumor intervening methods.
Get full access to this article
View all access options for this article.
